Eli Lilly (LLY) Non-Current Assets (2009 - 2026)

Eli Lilly (LLY) has reported Non-Current Assets for 18 consecutive years, with $61.7 billion the latest figure, recorded in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $61.7 billion, up 28.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.5 billion (up 23.65% YoY), and the FY2025 annual result was $56.8 billion, up 23.65% from the prior year.
• Non-Current Assets was $61.7 billion for Q1 2026 at Eli Lilly, up from $56.8 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $61.7 billion in Q1 2026 and troughed at $29.8 billion in Q3 2022.
• Average Non-Current Assets over 5 years is $41.3 billion, with a median of $38.8 billion recorded in 2024.
• Year-over-year, Non-Current Assets dropped 1.85% in 2022 and rose 28.29% in 2026.
• Over 5 years, Non-Current Assets stood at $31.5 billion in 2022, then grew by 21.69% to $38.3 billion in 2023, then increased by 20.1% to $46.0 billion in 2024, then climbed by 23.65% to $56.8 billion in 2025, then gained by 8.61% to $61.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $61.7 billion in Q1 2026, $56.8 billion in Q4 2025, and $52.9 billion in Q3 2025.